TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Heart drug tafamidis tested in korean patients
Disease control CompletedThis study looked at how well the drug tafamidis works for Korean patients with a rare heart condition called ATTR-CM. Researchers tracked 13 patients who were already prescribed the drug to see if it improved heart function, symptoms, and quality of life. The goal was to underst…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 10:03 UTC
-
New heart drug safety checked in small indian study
Disease control CompletedThis study looked at the safety of a medicine called VyndaMx (tafamidis) for people with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Six adults in India took the medicine by mouth, and doctors tracked any side effects for 6 months. The goal was t…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Sponsor: Pfizer • Aim: Disease control
Last updated May 12, 2026 13:43 UTC